Abstract
Atherothrombosis-related diseases are one of the world’s leading causes of mortality, and thus the search for new therapeutic approaches in this area remains a very urgent task. Modern pharmacogenomic technologies make it possible to obtain valuable data on disease pathogenesis and optimal therapeutic approaches. One promising research direction is the study of the thromboxane A2 - thromboxane A synthase - thromboxane A2 receptor axis. This review summarizes the recent evidence and suggests that systematic works in this area are creating new and promising opportunities in the treatment of patients with cardiovascular diseases.
Keywords: Inhibitors of thromboxane A2-synthase, pharmacogenetics, thromboxane A synthase, thromboxane, cardiovascular diseases, prostaglandins.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases
Volume: 16 Issue: 2
Author(s): Dinara F. Mesitskaya, Abram L. Syrkin, Marina G. Aksenova, Yong Zhang, Andrey A. Zamyatnin Jr.*Philipp Y. Kopylov*
Affiliation:
- Sechenov First Moscow State Medical University, Moscow,Russian Federation
- Sechenov First Moscow State Medical University, Moscow,Russian Federation
Keywords: Inhibitors of thromboxane A2-synthase, pharmacogenetics, thromboxane A synthase, thromboxane, cardiovascular diseases, prostaglandins.
Abstract: Atherothrombosis-related diseases are one of the world’s leading causes of mortality, and thus the search for new therapeutic approaches in this area remains a very urgent task. Modern pharmacogenomic technologies make it possible to obtain valuable data on disease pathogenesis and optimal therapeutic approaches. One promising research direction is the study of the thromboxane A2 - thromboxane A synthase - thromboxane A2 receptor axis. This review summarizes the recent evidence and suggests that systematic works in this area are creating new and promising opportunities in the treatment of patients with cardiovascular diseases.
Export Options
About this article
Cite this article as:
Mesitskaya F. Dinara , Syrkin L. Abram , Aksenova G. Marina , Zhang Yong , Zamyatnin Jr. A. Andrey *, Kopylov Y. Philipp *, Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases, Cardiovascular & Hematological Agents in Medicinal Chemistry 2018; 16 (2) . https://dx.doi.org/10.2174/1871525716666180724115132
DOI https://dx.doi.org/10.2174/1871525716666180724115132 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Common Therapeutic Strategies in the Management of Sexual Dysfunction and Cardiovascular Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Associations of Two Common Polymorphisms in <i>MTHFR</i> Gene with Blood Lipids and Therapeutic Efficacy of Simvastatin
Current Pharmaceutical Design Novel Biomarkers in Cardiovascular Diseases: Going beyond Troponins and Natriuretic Peptides - Part 1
Current Topics in Medicinal Chemistry Structural and Functional Alteration of Blood Vessels Caused by Cigarette Smoking: An Overview of Molecular Mechanisms
Current Vascular Pharmacology Preconditioning of the Myocardium by Volatile Anesthetics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio
Current Medicinal Chemistry An Update on GABA Analogs for CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine Recent Nanoscale Carriers for Therapy of Alzheimer's Disease: Current Strategies and Perspectives
Current Medicinal Chemistry Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Paring Down Obesity and Metabolic Disease by Targeting Inflammation and Oxidative Stress
Current Neurovascular Research Mass Spectrometric Identification of Collagen Alpha-1 (III) Chain and Chondroitin Sulfate Proteoglycan-4 Nitration in Patients with Acute Pulmonary Embolism
Current Proteomics Portable Technologies for Self-Monitoring of Coagulation Time: A Review
Current Biotechnology Masked Hypertension and Diabetes
Current Hypertension Reviews Aging Blunts Ischemic-Preconditioning-Induced Neuroprotection Following Transient Global Ischemia in Rats
Current Neurovascular Research Eight-Year Follow-Up of an Initial Case with NF-κB Decoy Oligodeoxynucleotide Transfection After Coronary Stent Implantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Patents in Cartilage Regeneration
Recent Patents on Regenerative Medicine Biphasic Mechanisms of Neurovascular Unit Injury and Protection in CNS Diseases
CNS & Neurological Disorders - Drug Targets Current Diagnostic Investigation in Pulmonary Hypertension
Current Respiratory Medicine Reviews